9 unknown, 1 recruiting. 5 Not applicable, 3 Early Phase 1, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Unknown 4, Recruiting 1 |
| Early Phase 1 | 3 | Unknown 3 |
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow CD19 CAR-T: new trials by email Literature Review of CD19 CAR-T trials Research Report on CD19 CAR-T
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies CAR-T Autologous T cell injection - Acute Lymphoblastic Leukemia, Lymphoma | Not applicable | Recruiting | Hebei Senlang Biotechnology Inc., Ltd. | 50 | 2022-09-07 | 2025-06-24 |
| Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma Human CD19Targeted T Cells Injection - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Unknown | Hrain Biotechnology Co., Ltd. | 100 | 2021-08-09 | 2022-07-05 |
| Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation CAR-γδT - AML | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2020-12-16 | 2021-03-12 |
| Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Senl-h19 CAR-T - B-ALL | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 15 | 2020-12-03 | 2021-03-11 |
| Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia CD19 CAR-T - B-ALL | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2020-09-01 | 2020-09-14 |
| Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma CD19 CAR-T - Non-hodgkin's Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2020-06-30 | 2020-09-29 |
| Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T - Adult B Acute Lymphoblastic Leukemia | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 50 | 2020-04-01 | 2020-11-13 |
| CAR-T Cells in Treating Patients With Relapsed or Refractory NHL CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T - Refractory Indolent Adult Non-Hodgkin Lymphoma | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 100 | 2020-04-01 | 2020-11-13 |
| CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia CD19 CAR-T, CD22 CAR-T, CD 19+22 - Childhood Acute Lymphoblastic Leukemia | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 50 | 2020-04-01 | 2020-11-13 |
| CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. Cyclophosphamide, Fludarabine, CD19 CAR-T - B-cell Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Henan Cancer Hospital | 20 | 2017-08-16 | 2017-10-20 |
Burkitt Lymphoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Recurrence (1)
Hebei Senlang Biotechnology Inc., Ltd. (8) · Henan Cancer Hospital (1) · Hrain Biotechnology Co., Ltd. (1)
China (10)
Jianmin Luo, PhD&MD (2) · Peihua Lu, PhD&MD (2) · Peihua MD Lu, PhD (2) · Peng Liu, M.D. & Ph.D. (1)